Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Retatrutide has attracted research interest because it is described as a triple agonist, meaning it is studied in relation to three distinct receptor systems rather than one
They are carefully selected by IPC and have gone through our rigorous negotiating process to make sure you get the best deal
The prescription starts the weight loss
Dose-Dependent Adverse Event Patterns One of the clearest findings from published retatrutide data is the dose-dependent relationship with adverse events: Lower doses (1 mg): GI event rates only modestly above placebo Mid-range doses (4-8 mg): GI event rates of 57-64%, with dose escalation reducing peak incidence Highest dose (12 mg): GI event rates of ~67%, though most events were mild-to-moderate and transient The Phase 2 trial included both "single-dose" and "escalated-dose" cohorts for the 4 mg and 8 mg groups
US$ 28.46
US$ 23.32
US$ 24.05
